Cagrilintide 5mg + Semaglutide 10mg Research Peptide: A Dual‑Mechanism Combination for Metabolic & Obesity Studies

If your research explores complementary pathways in appetite regulation, energy balance, and glycaemic control, the Cagrilintide 5mg + Semaglutide 10mg research peptide — known in clinical research as CagriSema — offers a precisely formulated, dual‑mechanism experimental platform. This fixed‑dose combination unites two mechanistically distinct peptide therapeutics: Cagrilintide, a long‑acting amylin and calcitonin receptor agonist (DACRA) that induces satiety through brainstem pathways, and Semaglutide, a potent GLP‑1 receptor agonist that reduces food intake and improves glycaemic control.

By targeting both the amylin/calcitonin system and the incretin pathway, this combination allows researchers to model the synergistic interplay that governs appetite suppression and metabolic regulation, providing deeper insight into the regulatory circuits that drive weight loss and glycaemic improvement.

At Chinese Grey Peptides, we supply high‑purity Cagrilintide 5mg + Semaglutide 10mg research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to >99% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into metabolic regulation, satiety signalling, and obesity research begin with uncompromising quality.

What Is the Cagrilintide + Semaglutide Combination and How Does It Work?

To fully appreciate the research potential of the Cagrilintide 5mg + Semaglutide 10mg research peptide, it is essential to understand the distinct yet complementary mechanisms of its two components.

Cagrilintide: The Dual Amylin & Calcitonin Receptor Agonist (DACRA)

Cagrilintide (AM833) is a long‑acting, lipidated analogue of the pancreatic hormone amylin. It is engineered as a dual amylin and calcitonin receptor agonist (DACRA) , binding non‑selectively to amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR). Research demonstrates that cagrilintide has an amylin‑like binding mode but induces distinct conformational dynamics at calcitonin‑family receptors compared to other peptides.

Mechanism of Action: Cagrilintide activates Gs‑coupled signalling pathways through both CTR and AMY1R, increasing intracellular cAMP. It exerts its effects on energy balance through the dorsal vagal complex (DVC) of the brainstem, where long‑term treatment upregulates prolactin‑releasing hormone (Prlh) expression in conserved neuronal populations. In clinical research, cagrilintide monotherapy (2.4 mg) has been shown to induce 11.8% weight loss over 68 weeks.

Semaglutide: The GLP‑1 Receptor Agonist

Semaglutide is a well‑established GLP‑1 receptor agonist with proven weight‑loss and cardiovascular benefits at a dose of 2.4 mg. It reduces appetite, delays gastric emptying, and improves glycaemic control through GLP‑1 receptor activation. In the landmark REDEFINE 1 trial, semaglutide monotherapy (2.4 mg) achieved 16.1% weight loss over 68 weeks.

Mechanism of Synergy: Dual‑Pathway Satiety Signalling

The scientific rationale for combining cagrilintide and semaglutide lies in their convergent yet distinct mechanisms:

• Cagrilintide targets the amylin/calcitonin system, activating brainstem pathways that induce satiety and reduce food intake through a non‑incretin mechanism.

• Semaglutide targets the GLP‑1 system, reducing appetite, improving glycaemic control, and promoting weight loss through well‑characterised incretin pathways.

• Complementary Mechanisms: Both peptides reduce appetite via distinct but complementary pathways — cagrilintide through brainstem amylin receptors and semaglutide through hypothalamic GLP‑1 receptors.

• Greater Efficacy: In the phase 3 REDEFINE 1 trial, CagriSema (2.4 mg each) achieved 20.4% mean weight loss at week 68 compared to 3.0% with placebo — an estimated difference of 17.3 percentage points (P<0.001). In the REDEFINE 2 trial (1206 participants with type 2 diabetes), CagriSema resulted in 13.7% weight loss compared to 3.4% with placebo (estimated difference, −10.4 percentage points; P<0.001).

Key Research Applications for Cagrilintide + Semaglutide

The Cagrilintide 5mg + Semaglutide 10mg research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Obesity & Weight Regulation Research

Cagrilintide + semaglutide combination therapy has demonstrated robust, dose‑dependent weight loss across multiple phase 3 trials. Research applications include:

• Energy Balance Studies: Investigating how dual amylin and GLP‑1 receptor agonism modulates appetite, satiety, and energy expenditure.

• Satiety Signalling Pathways: Exploring the neural circuits and molecular mechanisms through which amylin receptor and GLP‑1 receptor activation synergistically reduce food intake.

• Combination Therapy Models: The combination of cagrilintide and semaglutide produces 22.7% weight loss in adherent populations.

• Comparative Studies: The REDEFINE 4 trial is comparing CagriSema (2.4 mg/2.4 mg) with tirzepatide 15 mg over 84 weeks.

2. Type 2 Diabetes & Glycaemic Control Research

CagriSema has demonstrated superior glycaemic outcomes across multiple phase 3 trials. Research applications include:

• HbA1c Reduction Studies: In REIMAGINE 1, CagriSema (2.4 mg each) achieved a 1.8 percentage point HbA1c reduction from baseline after 40 weeks.

• Glycaemic Control: In REDEFINE 2, 73.5% of patients in the CagriSema group achieved HbA1c levels of 6.5% or less, compared to 15.9% in the placebo group.

• Metabolic Syndrome Research: Studying the combination’s effects on multiple metabolic parameters including glucose, lipids, and blood pressure.

3. Cardiovascular & Inflammatory Research

CagriSema has demonstrated beneficial cardiovascular effects in clinical research. Research applications include:

• Blood Pressure Reduction: A post‑hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure over 68 weeks.

• Inflammatory Markers: CagriSema reduced high‑sensitivity C‑reactive protein (hsCRP), an inflammatory marker associated with cardiovascular risk, by nearly 70%.

• Blood Pressure Medication Reduction: Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial.

4. Combination & Add‑On Therapy Research

CagriSema has been investigated across multiple clinical contexts:

• Add‑On to Basal Insulin: Cagrilintide–semaglutide provided bodyweight reductions of 10‑12% as an add‑on to basal insulin in adults with type 2 diabetes.

• East Asian Populations: REDEFINE 5 is assessing the fixed‑dose combination in east Asian populations.

• Paediatric Research: A phase 2 trial is investigating CagriSema for weight management in children and adolescents with overweight or obesity.

Chemical & Physical Specifications for Cagrilintide 5mg + Semaglutide 10mg

Accurate characterisation of the Cagrilintide 5mg + Semaglutide 10mg research peptide is essential for reproducible experimental design.

Note: The 5 mg and 10 mg masses refer to the weight of each component in its lyophilised form. The blend is supplied as a fixed‑dose combination in a single lyophilised vial. This ratio reflects the clinical research formulation of CagriSema (2.4 mg cagrilintide + 2.4 mg semaglutide in the 1:1 ratio, scaled proportionally for research purposes). For research use only (RUO). Not for human consumption. CagriSema is not FDA‑approved for therapeutic use.

Reconstitution & Handling Protocol for Cagrilintide + Semaglutide

Proper reconstitution of the Cagrilintide 5mg + Semaglutide 10mg research peptide is critical for maintaining the structural integrity and biological activity of both components.

Step 1 – Preparation

• Bring the sealed blend vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the blend vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 15 mg per 1.5 mL of diluent, yielding a 10 mg/mL total peptide concentration.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted peptide blend into single‑use sterile vials.

• Store aliquots at –20°C for up to 1 month or at –80°C for up to 6 months.

• Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for Cagrilintide 5mg + Semaglutide 10mg

Adjust diluent volume based on your experimental requirements. The exact concentration of each individual peptide within the blend is 5 mg cagrilintide and 10 mg semaglutide per 15 mg vial.

Storage & Stability Guidelines for Cagrilintide 5mg + Semaglutide 10mg

Why Choose Chinese Grey Peptides for Cagrilintide + Semaglutide?

As an authentic licensed peptide supplier based in the USA, we supply the Cagrilintide 5mg + Semaglutide 10mg research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed >99% for each component, every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO). CagriSema is not FDA‑approved for therapeutic use and is supplied for research purposes only.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: Cagrilintide 5mg + Semaglutide 10mg Research Peptide

 What is the Cagrilintide 5mg + Semaglutide 10mg research peptide?
It is a research‑grade, fixed‑dose combination of cagrilintide (a dual amylin and calcitonin receptor agonist) and semaglutide (a GLP‑1 receptor agonist). Known clinically as CagriSema, it is used as a dual‑pathway tool to study appetite suppression, energy balance, glycaemic control, and obesity.

 How does each component work?
Cagrilintide binds to amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR), activating Gs‑signalling pathways that induce satiety through brainstem pathways. Semaglutide activates GLP‑1 receptors, reducing appetite, delaying gastric emptying, and improving glycaemic control.

What is the proposed synergy between cagrilintide and semaglutide?
Cagrilintide targets the amylin/calcitonin system through non‑incretin pathways, while semaglutide targets the GLP‑1 system. Together, they reduce energy intake and appetite through complementary mechanisms. Clinical trials have demonstrated significantly greater weight loss and glycaemic control with the combination compared to either component alone.

 What clinical trial data support the CagriSema combination?
In the phase 3 REDEFINE 1 trial, CagriSema achieved 20.4% mean weight loss versus 3.0% with placebo in 3417 adults without diabetes (P<0.001). In REDEFINE 2, it achieved 13.7% weight loss versus 3.4% with placebo in 1206 adults with type 2 diabetes (P<0.001). In REIMAGINE 1, CagriSema demonstrated a 1.8 percentage point HbA1c reduction.

What cardiovascular effects has CagriSema demonstrated?
A post‑hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure and nearly 70% reduction in hsCRP, an inflammatory marker.

 What purity does your Cagrilintide + Semaglutide blend meet?
Each component is tested to >99% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute this peptide blend?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

 How should I store reconstituted peptide blends?
Reconstituted blends should be stored at –20°C for up to 1 month or at –80°C for up to 6 months. Aliquot immediately into single‑use vials and avoid repeated freeze‑thaw cycles.

 Is this peptide blend legal to purchase in the USA for research?
Yes. This blend is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: CagriSema is an investigational compound and is not FDA‑approved for therapeutic use.

Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• Novo Nordisk CagriSema filing notice
• Novo Nordisk annual report
• DailyMed Wegovy semaglutide label
• FDA Summit Research Peptides warning letter
• FDA Xcel Research warning letter
• Google Merchant Listing Structured Data
• Rank Math WooCommerce Product Schema

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

Important Compliance Notice

Cagrilintide 5mg Semaglutide 10mg Blend may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, weight-loss claims, obesity claims, glucose claims, diabetes claims, appetite claims, metabolic claims, body-composition claims, fat-loss claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, sport-governing rules, labeling rules, and permitted-use requirements before ordering.

From its innovative design as a fixed‑dose combination of two mechanistically distinct receptor agonists to its well‑documented role in modelling the synergistic interplay between the amylin/calcitonin system and the GLP‑1 pathway, the Cagrilintide 5mg + Semaglutide 10mg research peptide provides a uniquely versatile platform for advanced metabolic and obesity research.

Its ability to induce significant weight loss and improve glycaemic control through complementary pathways—supported by large‑scale phase 3 clinical trials published in the New England Journal of Medicine and The Lancet Diabetes & Endocrinology—makes it a valuable addition to any laboratory investigating appetite regulation, energy balance, obesity pathophysiology, or type 2 diabetes. By choosing high‑purity, lab‑verified Cagrilintide 5mg + Semaglutide 10mg research peptide from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with the Cagrilintide + Semaglutide blend? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade research peptides delivered directly to your facility in the USA, UK, or Europe.